Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from QHSLab ( (USAQ) ) is now available.
On January 6, 2026, QHSLab issued an unaudited financial and operational update ahead of an investor session, reporting that revenue for the nine months ended September 30, 2025 rose 32% year over year to $1.99 million, with gross profit of $1.32 million at a 66% margin, net operating income before interest of $95,738, and approximately $630,000 in cash as of December 31, 2025. During the fourth quarter of 2025, the company nearly eliminated its outstanding convertible debt, cutting it from about $1.4 million to $20,000 and thereby significantly reducing interest expense, while management indicated the business exited 2025 in a cash-flow-positive operating position and highlighted a capital structure consisting of 13.4 million shares outstanding, a relatively small public float, and a sizable block of restricted shares from recent financings and debt conversions.
The most recent analyst rating on (USAQ) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on QHSLab stock, see the USAQ Stock Forecast page.
Spark’s Take on USAQ Stock
According to Spark, TipRanks’ AI Analyst, USAQ is a Neutral.
The score is primarily held back by weak financial quality—ongoing net losses and negative equity despite improving revenue, margins, and positive free cash flow. Technicals are strong but overextended (very high RSI/Stoch), while valuation remains challenged due to losses and no dividend. Corporate actions to reduce convertible debt and raise equity modestly improve the risk profile.
To see Spark’s full report on USAQ stock, click here.
More about QHSLab
QHSLab, Inc. (OTCQB: USAQ) is a digital health infrastructure company that provides preventive screening, assessment, and workflow solutions for primary care practices. Its platform supports care delivered outside the exam room—such as screening, monitoring, education, and follow-up—across multiple underdiagnosed conditions, in a scalable, documented, and reimbursable manner.
Average Trading Volume: 18,668
Technical Sentiment Signal: Buy
Current Market Cap: $9.59M
See more insights into USAQ stock on TipRanks’ Stock Analysis page.